Table 1.
Prognostic studies in breast cancer looking at HIF-1α and HIF-2α overexpression detected via immunohistochemistry
| Group | Tumor type | Number of cases | Overall outcome | Association of marker on multivariate analysis |
|---|---|---|---|---|
| Schindl et al. [90] |
LN+ early BC | 206 | Unfavorable prognosis for HIF-1α. HIF-2α not assessed | DFS HR = 1.4; P = 0.001 |
| Trastour et al. [91] |
Early BC | 132 | Unfavorable prognosis for HIF-1α. HIF-2α not assessed | DFS HR = 4.2; P < 0.001 |
| Bos et al. [92] | Stage 1-2 early BC | 150 | Trend toward unfavorable prognosis for HIF-1α (significant for LN- patients). HIF-2α not assessed |
OS HR = 2.16; P = 0.12 DFS HR = 1.67; P = 0.12 |
| Generali et al. [36] | T2-4 N0-1 early BC | 187 | Unfavorable prognosis for CAIX. Treatment response for HIF-1α. HIF-2α not assessed | DFS (CAIX) HR = NR; P = 0.02 Clinical response to treatment (HIF-1α): P < 0.05 |
| Gruber et al. [93] | LN+ early BC | 77 | Trend toward unfavorable prognosis for HIF-1α. HIF-2α not assessed | OS HR = 2.66; P = 0.09 DFS HR = 1.68; P = 0.30 |
| Yamamoto et al. [94] | Early BC | 171 | Unfavorable prognosis for HIF-1α. HIF-2α not assessed | OS HR = 2.15; P = 0.02 DFS HR = 1.59; P = 0.02 |
| Jubb et al. [3] | Meta-analysis | 923 | Trend toward unfavorable prognosis for HIF-1α. HIF-2α not assessed | OS HR = 1.80 (95% CI 1.32 to 2.47) |
| Schoppmann et al. [95] | LN+ early BC | 119 | Unfavorable prognosis for HIF-1α | OS HR = NR; P = 0.03 DFS HR = NR; P = 0.04 |
| Vleugel et al. [21] |
Early BC | 166 | Unfavorable prognosis for HIF-1α | DFS HR = 2.23; P = 0.01 |
| Dales et al. [96] | Early BC | 745 | Unfavorable prognosis for HIF-1α | OS HR = NR; P = 0.030 DFS HR = NR; P = 0.158 |
| Helczynska et al. [97] | Early BC | 512 | Unfavorable prognosis for HIF-2α. No significant association for HIF-1α | BCSS (HIF-2α) HR = 2.3; P = 0.003 DFS (HIF-2α) HR = 1.6; P = 0.03 |
BC, breast cancer; BCSS, breast cancer-specific survival; CI, confidence interval; LN+, lymph node positive; LN-, lymph node negative; DFS, disease free survival; HR, hazard ratio; NR, not reported; OS, overall survival.